Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

1,356 recalls, newest first

Class II · Moderate risk

Phentermine HCL Blue/White Capsules

CGMP Deviations: Light sensitive drug products repackaged in transparent/partially transparent pouches.

Terminated cGMP deviation Calvin Scott & Company, Inc. NDC 10702-0029-10 D-1529-2020
Class II · Moderate risk

Phentermine HCL Blue/Clear capsules

CGMP Deviations: Light sensitive drug products repackaged in transparent/partially transparent pouches.

Terminated cGMP deviation Calvin Scott & Company, Inc. NDC 10702-0028-10 D-1528-2020
Class II · Moderate risk

Phentermine HCL Yellow Caps 30mg

CGMP Deviations: Light sensitive drug products repackaged in transparent/partially transparent pouches.

Terminated cGMP deviation Calvin Scott & Company, Inc. NDC 51224-0202-70 D-1527-2020
Class II · Moderate risk

Phentermine HCL GrayYellow capsules

CGMP Deviations: Light sensitive drug products repackaged in transparent/partially transparent pouches.

Terminated cGMP deviation Calvin Scott & Company, Inc. NDC 51224-0203-70 D-1526-2020
Class II · Moderate risk

Phentermine 15mg grey/Yellow Capsules

CGMP Deviations: Light sensitive drug products repackaged in transparent/partially transparent pouches.

Terminated cGMP deviation Calvin Scott & Company, Inc. NDC 11534-0157-03 D-1525-2020
Class II · Moderate risk

Phentermine HCL Gray/Yellow capsules

CGMP Deviations: Light sensitive drug products repackaged in transparent/partially transparent pouches.

Terminated cGMP deviation Calvin Scott & Company, Inc. NDC 10702-0026-10 D-1524-2020
Class II · Moderate risk

Phendimetrazine Brown/Clear Capsules

CGMP Deviations: Light sensitive drug products repackaged in transparent/partially transparent pouches.

Terminated cGMP deviation Calvin Scott & Company, Inc. NDC 69543-0409-11 D-1523-2020
Class II · Moderate risk

Phendimetrazine Yellow Tabs 35mg

CGMP Deviations: Light sensitive drug products repackaged in transparent/partially transparent pouches.

Terminated cGMP deviation Calvin Scott & Company, Inc. NDC 69543-0410-11 D-1522-2020
Class II · Moderate risk

Phendimetrazine Yellow Tabs 35mg

CGMP Deviations: Light sensitive drug products repackaged in transparent/partially transparent pouches.

Terminated cGMP deviation Calvin Scott & Company, Inc. NDC 0702-0077-10 D-1521-2020
Class II · Moderate risk

Topiramate 25mg Tabs White/round tablets

CGMP Deviations: Light sensitive drug products repackaged in transparent/partially transparent pouches.

Terminated cGMP deviation Calvin Scott & Company, Inc. NDC 47335-0707-13 D-1520-2020
Class II · Moderate risk

Thyroid Neutral Tabs 2 gr

CGMP Deviations: Light sensitive drug products repackaged in transparent/partially transparent pouches.

Terminated cGMP deviation Calvin Scott & Company, Inc. NDC 64727-3308-02 D-1519-2020
Class II · Moderate risk

Thyroid 1 Gr tablets

CGMP Deviations: Light sensitive drug products repackaged in transparent/partially transparent pouches.

Terminated cGMP deviation Calvin Scott & Company, Inc. NDC 64727-3300-01 D-1518-2020
Class II · Moderate risk

Thyroid 1 Grain Tablets

CGMP Deviations: Light sensitive drug products repackaged in transparent/partially transparent pouches.

Terminated cGMP deviation Calvin Scott & Company, Inc. NDC 64727-3300-02 D-1517-2020
Class II · Moderate risk

Hydrochlorothiazide 50mg tablets

CGMP Deviations: Light sensitive drug products repackaged in transparent/partially transparent pouches.

Terminated cGMP deviation Calvin Scott & Company, Inc. NDC 16729-0184-17 D-1516-2020
Class II · Moderate risk

Hydrochlorothiazide

CGMP Deviations: Light sensitive drug products repackaged in transparent/partially transparent pouches.

Terminated cGMP deviation Calvin Scott & Company, Inc. NDC 29300-0128-10 D-1515-2020
Class II · Moderate risk

Hydrochlorothiazide 25mg tablets

CGMP Deviations: Light sensitive drug products repackaged in transparent/partially transparent pouches.

Terminated cGMP deviation Calvin Scott & Company, Inc. NDC 16729-0183-17 D-1514-2020
Class II · Moderate risk

Vilamit Mb

cGMP deviations

Terminated cGMP deviation Vilvet Pharmaceuticals Inc. NDC 71186-002-35 D-1487-2020
Class II · Moderate risk

Auryxia (ferric citrate)

cGMP deviations: Lots recalled were not manufactured in conformance with the FDA-approved manufacturing process for Auryxia.

Terminated cGMP deviation Keryx Biopharmaceuticals, Inc. D-1389-2020
Class II · Moderate risk

Vardenafil 20 mg Troche

Lack of Processing Controls (lack of assurance of conformity to specifications).

Terminated cGMP deviation MasterPharm LLC D-1442-2020

Recalls by year